|Articles|August 1, 2006

VTE PROPHYLAXIS NOW RECOMMENDED FOR CANCER PATIENTS

The National Comprehensive CancerNetwork (NCCN) recently issued guidelinesrecommending inpatient prophylacticanticoagulation therapy withunfractionated heparin, low-molecularweightheparin (LMWH), or fondaparinux.The guidelines do not address outpatientprophylaxis, but they suggestimmediate and long-term treatmentonce an episode of venous thromboembolism(VTE) occurs. The NCCN recommends3 to 6 months of treatment fordeep vein thrombosis, 6 to 12 months oftreatment for pulmonary embolism, andindefinite treatment for patients withactive cancer or persistent risk factors.

The NCCN recommends the use ofLMWH or warfarin for long-term treatmentand secondary prevention. Preliminarydata suggest an improved survivalbenefit using LMWH, however. Thenew guidelines may be accessed atwww.nccn.org/professionals/physician_gls/sPDF/vte.pdf.

Dr. Garrett is a clinical pharmacistpractitioner at Cornerstone Health Carein High Point, NC.

Articles in this issue

about 19 years ago

Article

Questions and Answers About Dry Mouth

about 19 years ago

Article

Kidney Stone

about 19 years ago

Article

Rx Products

about 19 years ago

Article

can you READ these Rxs?

about 19 years ago

Article

OTC Products

about 19 years ago

Article

compounding HOTLINE

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME